Novo wants FDA approval to use Victoza with long-acting insulin

06/28/2011 | Reuters

Novo Nordisk filed for FDA approval to promote once-daily injectable drug Victoza with a long-acting insulin to treat type 2 diabetes. "The study that forms the basis for [this application] was a study with our own long-acting insulin, Levemir," said spokesman Mike Rulis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY